Information was received from a foreign healthcare provider (hcp) via a manufacturer's representative regarding a patient who was receiving baclofen (unknown concentration and dose) via an implantable pump for an unknown indication for use.It was reported motor stall was seen an initial interrogation.The pump was reported to have started stalling on (b)(6) 2019 and was stalling and recovering on and off.On (b)(6) 2019, it was noticed the pump was currently stalled, starting on (b)(6) 2019.The patient did not recently have an mri.The patient had more spasticity from the initial stall, but on (b)(6) 2019 when in office, they did not have any symptoms.It was stating troubleshooting was not possible due to lack of access to product.Further complications were not reported.Additional information was received.The patient's pump was implanted in (b)(6) 2013.The pump was scheduled to be replaced on (b)(6) 2019.The event had not yet resolved.The patient was on minimum daily dose.No other contributing factors to the event had been identified.Pump return was to be determined following explant.Additional information was received.The patient was admitted to the hospital on (b)(6) 2019.The patient began experiencing shortness of breath and sweating.The patient was admitted to monitor symptoms.The patient was later admitted to the intensive care unit (icu) and intubated.The pump replacement was now scheduled for (b)(6) 2019.Additional information was received.The patient's pump was replaced on (b)(6) 2019 and was to be returned for analysis.At the time of the report on (b)(6) 2019, the patient remained in the hospital for monitoring.
|